Analysis of the current situation and countermeasures of pediatric drug procurement in China under the background of centralized drug procurement

LIU Jungang; YANG Xingyi; HUANG Jieying; XU Wei

doi:10.6039/j.issn.1001-0408.2023.24.05

您当前的位置：

首页 >

文章列表页 >

Analysis of the current situation and countermeasures of pediatric drug procurement in China under the background of centralized drug procurement

更新时间：2023-12-22

- Analysis of the current situation and countermeasures of pediatric drug procurement in China under the background of centralized drug procurement
- ZHONGGUO YAOFANG Vol. 34, Issue 24, Pages: 2982-2986(2023)
- 作者机构：
  
  中国药科大学国际医药商学院，南京　211198
- 作者简介：
- 基金信息：
- DOI：10.6039/j.issn.1001-0408.2023.24.05
  CLC： R95;R985
- Published：30 December 2023，
  
  Received：01 July 2023，
  
  Revised：23 October 2023，
扫描看全文
刘俊刚,杨星怡,黄洁莹等.集采背景下我国儿童药品采购现状及对策分析 ^Δ[J].中国药房,2023,34(24):2982-2986.

LIU Jungang,YANG Xingyi,HUANG Jieying,et al.Analysis of the current situation and countermeasures of pediatric drug procurement in China under the background of centralized drug procurement[J].ZHONGGUO YAOFANG,2023,34(24):2982-2986.
刘俊刚,杨星怡,黄洁莹等.集采背景下我国儿童药品采购现状及对策分析 ^Δ[J].中国药房,2023,34(24):2982-2986. DOI： 10.6039/j.issn.1001-0408.2023.24.05.

LIU Jungang,YANG Xingyi,HUANG Jieying,et al.Analysis of the current situation and countermeasures of pediatric drug procurement in China under the background of centralized drug procurement[J].ZHONGGUO YAOFANG,2023,34(24):2982-2986. DOI： 10.6039/j.issn.1001-0408.2023.24.05.

摘要

目的

分析我国药品集中带量采购（简称“集采”）背景下儿童药品使用现状，为后续儿童药品集采规则的设计提供参考。

方法

采用比较分析法，比较集采中选结果和儿童药品实际使用现状、儿童药品差比价和挂网价，分析儿童药品在集采和临床使用供应中的问题，并对儿童药品集采和定价规则的优化提出建议。结果与

结论

我国儿童药品需求增大，但已上市儿童药品供给不足（包括疾病领域覆盖不足、品种不足、儿童适宜剂型不足、儿童适宜规格不足等），且儿童药品研发较为困难。按照医保目录合并剂型集采后，部分儿童适宜剂型和规格无法中选，导致临床儿童用药短缺，相关企业研发生产儿童药品和参与挂网竞争的积极性降低。另外，在现有药品差比价规则下，未中选儿童药品的定价也存在过低的现象。建议在进行药品集采时，应基于儿童药品属性和适应证覆盖人群，对儿童专用药品进行单独分组集采；将未中选儿童适宜药品品规按一定比例折算入医疗机构约定采购量，并进一步优化儿童专用药品定价规则，确保该类药品有一定的利润空间，提高生产企业的研发供应意愿，从而保障儿童药品的使用供应。

Abstract

OBJECTIVE

To analyze the current situation of pediatric drug use under centralized drug procurement， and to provide reference for the subsequent design of pediatric drug centralized procurement rules.

METHODS

The comparative analysis method was used to analyze the problems in the centralized procurement， clinical use and supply of pediatric drugs from the aspects of centralized procurement selection results and actual use of pediatric drugs， price difference and online prices of pediatric drugs. The solutions were put forward to optimize the centralized procurement and pricing rules of pediatric drugs.

RESULTS &

CONCLUSIONS

The demands for pediatric drugs in China were increasing， but the supply of marketed pediatric drugs was insufficient （including insufficient coverage of disease fields， insufficient varieties， insufficient suitable dosage forms for children， insufficient specifications for children， etc.）， and the development of pediatric drugs was relatively difficult. After merging the dosage forms of centralized procurement according to the medical insurance list， some suitable dosage forms and specifications for children couldn’t be selected， resulting in a shortage of clinical pediatric medication. Relevant enterprises’ enthusiasm for developing and producing pediatric drugs and participating in online competitions had decreased. There was also the problem of underpricing of pediatric drugs under the drug price difference ratio rule. It is recommended that when conducting centralized drug procurement， special drugs for children should be grouped separately for centralized procurement based on attributes and the population covered by the indications. The specifications of suitable pediatric drugs that were not selected are converted into the agreed purchase quantity of medical institutions in a certain proportion. It is necessary to further optimize the pricing rules for pediatric specialized drugs， ensure a certain profit margin for such drugs， increase the willingness of production enterprises to research， develop and supply drugs， and thus ensure the use and supply of pediatric drugs.

关键词

集中带量采购儿童药品差比价定价短缺

Keywords

pediatric drugprice difference ratiopricingshortage

references

李赛赛，徐伟，杜雯雯，等. 我国儿童基本药物的可获得性研究：基于全国19省份的调查分析[J]. 中国卫生政策研究，2018，11（12）：12-18.

LI S S，XU W，DU W W，et al. Study on the availability of pediatric essential medicines in China：based on the surveys in 19 provinces[J]. Chin J Health Policy，2018，11（12）：12-18.

胡娅娅，江牧. 儿童药品包装设计中的修辞性叙事[J]. 包装工程，2022，43（8）：225-230，265.

HU Y Y，JIANG M. Rhetorical narrative in children’s drug packaging design[J]. Packag Eng，2022，43（8）：225-230，265.

陈哲，李思雨，李海龙，等. 四川省儿童用药品研发生产和使用现状调查[J]. 中国循证医学杂志，2023，23（5）：497-503.

CHEN Z，LI S Y，LI H L，et al. The development，production and use of medicine for children in Sichuan Province：a across-sectional study[J]. Chin J Evid Based Med，2023，23（5）：497-503.

关玮伟，宋子扬，梅冬，等. 儿童医院口服药品分剂量现状调查与分析[J]. 儿科药学杂志，2022，28（2）：26-30.

GUAN W W，SONG Z Y，MEI D，et al. Investigation and analysis on drug manipulation for pediatric oral dosing in pediatric hospitals[J]. J Pediatr Pharm，2022，28（2）：26-30.

曾卫强，王夏影，陈锦金，等. 某妇幼保健院口服片剂分剂量的现状及对策分析[J]. 广东药科大学学报，2022，38（6）：25-30.

ZENG W Q，WANG X Y，CHEN J J，et al. Analysis of the current situation and countermeasures of oral tablet subdosing in a maternal and child health center[J]. J Guangdong Pharm Univ，2022，38（6）：25-30.

卫陈，顾海. 基于解释结构模型的儿童用药有效供给制约因素分析[J]. 中国全科医学，2015，18（31）：3872-3875.

WEI C，GU H. Restraining factors for the effective supply of drug for children based on interpretative structural mo-deling[J]. Chin Gen Pract，2015，18（31）：3872-3875.

马瑞娟，黄伟，段彦彦，等. 药品集中带量采购政策在儿童专科医院实施现状：以某三甲儿童专科医院为例[J]. 儿科药学杂志，2023，29（6）：19-22.

MA R J，HUANG W，DUAN Y Y，et al. Implementation status of centralized drug quantity purchase policy in chil-dren’s hospitals：taking a grade three，class A children’s hospital as an example[J]. J Pediatr Pharm，2023，29（6）：19-22.

张焕波，张岳洋，孙珮. 加快完善药品和医用耗材集中带量采购制度[J]. 中国物价，2023（7）：68-71.

ZHANG H B，ZHANG Y Y，SUN P. Speed up the improvement of the volume-based procurement system for drugs and medical consumables[J]. China Price，2023（7）：68-71.

汤少梁，朱亚，冯莉钧，等. 基于供给侧改革的我国儿童用药安全性与可及性优化路径研究[J]. 中国医药导报，2017，14（35）：125-129.

TANG S L，ZHU Y，FENG L J，et al. The optimization path of safety and accessibility of pediatric drugs in China based on the supply side reform research[J]. China Med Her，2017，14（35）：125-129.

任延峰，杨毅，明坚，等. 药品集中采购政策的WHO经验及启示[J]. 卫生经济研究，2022，39（6）：17-19.

REN Y F，YANG Y，MING J，et al. Experience of WHO about volume-based drug procurement policy[J]. Health Econ Res，2022，39（6）：17-19.

张宸，凡馨，金秋晨，等. 日本儿童药定价及价格激励政策对我国的启示[J]. 中国药房，2021，32（23）：2822-2827.

ZHANG C，FAN X，JIN Q C，et al. Pediatric drug pricing and price incentive policy in Japan and its enlightenment to China[J]. China Pharm，2021，32（23）：2822-2827.

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

基于销售终端视角浅议如何解决基本药物短缺问题

具备执业药师资格的专业教师注册执业的探讨

辽宁省国家基本药物制度实施现状及其保障措施研究

Related Author

谢小东邵蓉

林瑾文郑孝勇罗格莲

王迎王淑玲

Related Institution

No data

Address：8/F,129 Daping Main Street,Yuzhong District,Chongqing 400042,P.R.China
Technical support is provided by Beijing Founder Electronics co., LTD 渝ICP备15012710号公网安备50010302001817
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰